Leerink raised the firm’s price target on uniQure (QURE) to $68 from $48 and keeps an Outperform rating on the shares. The topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington’s disease are a game-changer and a definitive win for uniQure, the analyst tells investors in a research note. The firm continues to see these data as definitive, clearly making a difference on progression across multiple measures of function and cognition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- uniQure price target raised to $65 from $30 at Stifel
- uniQure’s AMT-130 Gene Therapy Shows Promising Results in Huntington’s Disease Trials, Justifying Buy Rating and $70 Price Target
- uniQure has leading candidate in Huntington’s, says H.C. Wainwright
- Leerink says uniQure stock could trade up 100% on HD study data